Table 2.

Association between increase in cfDNA concentration (5 ng/mL) or in cfDNA fragment size (5 bp) and prostate cancer status. Results from crude univariate and adjusted multivariate logistic regression analyses (adjusted for age, and PSA when available).

cfDNA measure	Prostate cancer status	Variable	Crude			Adjusted
			Odds ratio (95% CI)		P-value	Odds ratio (95% CI)	P-value
cfDNA concentration (5 ng/mL)	Localized vs healthy	cfDNA concentration	1.10 (0.82–1.61)		0.64	1.05 (0.77–1.69)*	0.72
		Age	–		–	1.54 (1.10–2.10)	0.01
	mCRPC vs healthy	cfDNA concentration	1.93 (1.34–3.18)		0.0025	1.69 (1.16–2.93)*	0.034
		Age	–		–	2.39 (1.69–3.43)	1E–06
	mCRPC vs localized	cfDNA concentration	1.47 (1.22–2.01)		0.0017	1.34 (1.05–1.76)†	0.027
		Age	–		–	1.76 (1.28–2.60)	0.002
		PSA	–		–	1.54 (1.22–2.01)	0.0008
cfDNA fragment size (5 bp)	Localized vs healthy	cfDNA Fragment size	0.86 (0.73–0.9)		0.003	0.77 (0.66–0.90)*	0.0008
		Age	–		–	1.61 (1.22–2.10)	0.001

*Adjusted for age.

^†Adjusted for age and PSA.